Ampullary (Ampulla of Vater)

(101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors

(108-20) A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

(115-CA) A phase 1/2 study of RTX-224 for the treatment of patients with advanced solid tumors

(127-21) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

(130-21) A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations

(131-21) Tumor-Agnostic precision immuno-oncology and somatic targeting rational for you (tapistry) Phase II platform trial

(141-21) A phase 1/2 open label, multicenter study to assess the safety, pharmacokinetics, and antitumor activity of UCB6114 administered intravenously to participants with advanced solid tumors

(154-21) A Phase 1a/1b Dose Escalation/Expansion Study of TTX080, an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab or Cetuximab, in Patients with Advanced Solid Refractory/Resistant Malignancies

(155-17) APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

(158-21) A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in combination with Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects with Advanced/Metastatic EGFR-Expressing Cancers

(157-17) FID-007 in Treating Participants With Advanced Solid Tumors

(162-20) A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer

(160-21) A Phase 1 Study of ZN-c3 as a Single Agent in Subjects with Solid Tumors

(178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

(176-21) NP-G2-044 as Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

(187-17) Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

(187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

(188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

(188-20) A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

(196-21) A Phase 1 b/2 study of repotrectinib in combination with other anticancer therapies for the treatment of subjects with KRAS-Mutant advanced solid tumor (TRIDENT-2)

(209-20) First-In-Human Dose-Escalation Study of SRP1002 in Patients with Advanced-Stage Solid Tumors

(210-21) A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss

(213-20) A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

(220-21) A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes

(231-20) A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies

(243-20) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors

(256-21) The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

 

 

Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543